Article
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2024
Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, André T, Maddalena G, Mazzoli G, Intini R, Cohen R, Cercek A, Segal N H, Saltz L, Varghese A M, Yaeger R, Nusrat M, Goldberg Z, Ku G Y, El Dika I, Margalit O, Grinshpun A, Murtaza Kasi P, Schilsky R, Lutfi A, Shacham-Shmueli E, Khan Afghan M, Weiss L, Westphalen C B, Conca V, Decker B, Randon G, Elez E, Fakih M, Schrock A B, Cremolini C, Jayachandran P, Overman M J, Lonardi S, Pietrantonio F
Abstract excerpt
BACKGROUND: POLE and POLD1 proofreading deficiency (POLE/D1pd) define a rare subtype of ultramutated metastatic colorectal cancer (mCRC; over 100 mut/Mb). Disease-specific data about the activity and efficacy of immune checkpoint inhibitors (ICIs) in POLE/D1pd mCRC are lacking and it is unknown whether outcomes may be different from mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) mCRCs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.